表观遗传学药物FK228抗肿瘤作用的研究进展  

Research Progress in Anti-tumor Effect of Histone Deacetylase Inhibitor FK228

作　　者：刘魏然 尹化斌[1] LIU Wei-ran YIN Hua-bin(Shanghai Fifth People＇s Hospital, Fudan University, Shanghai 200240, Chin)

机构地区：[1]复旦大学附属上海市第五人民医院,上海200240

出　　处：《中国肿瘤》2017年第6期471-475,共5页China Cancer

基　　金：上海市闵行区卫生局自然科学研究课题(2016MHZ331)

摘　　要：组蛋白去乙酰化酶抑制剂具有众多生物学功能,如抗肿瘤、抗真菌、抗病毒、抗炎症等作用,其对肿瘤细胞表现出强大的功能。FK228作为一种新型组蛋白去乙酰化酶抑制剂,因其特殊的缩酯环肽结构,可有效透过细胞膜,通过抑制组蛋白去乙酰化酶而显示良好的抗肿瘤活性,同时仅引起轻微的不良反应,已经被美国FDA批准用于治疗外周及皮肤T-细胞淋巴瘤。全文就FK228在抗肿瘤方面取得的研究进展作一综述。Histone deacetylase inhibitors possess many biological properties,such as anti-tumor,antifungal,antiviral and anti-inflammatory functions. In particular,the potent effects of histone deacetylase inhibitors on tumor cells have led to researchers focusing on it. As a novel histone deacetylase inhibitor,FK228 has a special cyclic depsipeptide structure,and can pass through cytomembrane to exert an anti-tumor effect;meanwhile it may cause mild adverse reactions. FK228 has been approved by the US Food and Drug Administration（FDA） for treating peripheral and cutaneous T-cell lymphoma. This paper reviews the research progress of FK228 in cancer therapy.

关 键 词：FK228 组蛋白去乙酰化酶抑制剂 

分 类 号：R730.5[医药卫生—肿瘤]